AGPS and prostate cancer: The inactivation of AGPS can reduce the expression of various lipids, such as ether lipids, prostaglandins, and acyl phospholipids, which are essential for the growth and spread of tumor cells, reducing the pathogenicity of cancer at the same time, while overexpression of AGPS can increase the survival and motility of many tumor cells (such as breast cancer 231MFP cells, melanoma C8161 cells, prostate cancer PC3 cells, and primary breast cancer cells) and promote tumor growth and invasion [17].